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INTRODUCTION 
 
 
 Fishberg defined uremia in accord with its etymology and original 
meaning, as a complex of symptoms resulting from failing renal function caused 
by retention of constituents of normal urine52. It is a generalized symptom 
complex due to a dynamic imbalance between the organism’s current metabolism 
and appropriate renal function. Richard Bright first described the association 
between anaemia and chronic renal failure. A normocytic normochromic anaemia 
is present in majority of patients with chronic renal disease, usually observed 
when glomerular filtration rate falls below 30 ml/min52.   
 
 
 
 
 2
AIMS OF THE STUDY 
 
PRIMARY OBJECTIVE 
 
 Much of the morbidity and mortality in renal failure patients can be 
attributed to secondary consequences of chronic anaemia31. Other factors 
associated with chronic renal failure may contribute to development of anaemia 
but erythropoietin deficiency is by far the major factor. Life long replacement 
therapy with erythropoietin for anaemia correction in chronic renal failure is out 
of reach for most of our patients who belong to the lower socioeconomic strata.  
More over many other factors like malnutrition, iron deficiency etc., may be 
contributing to renal anaemia, correction of which can reduce morbidity due to 
anaemia considerabley42. The purpose of the study is to identify such additional 
risk factors of anaemia in chronic renal failure. 
RATIONALE 
 By this study, we try to analyze on morphological and distribution patterns 
of anaemia and its correctable contributing factors if any, so that some benefits 
can be extended to non affluent renal disease patients also. 
STUDY DESIGN 
1. Primary objective 
2. Secondary objective 
To find out morphological and various distributing patterns of anaemia in 
renal disease. 
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REVIEW OF LITERATURE 
 
INTRODUCTION 
 
 Chronic renal failure is a pathophysiological process with multiple 
aetiologies resulting in the inexorable attrition of nephron number and function, 
and frequently leading to end stage renal disease (ESRD).  ESRD represents a 
clinical state or condition in which there has been an irreversible loss of 
endogenous renal function, of a degree sufficient to render the patient 
permanently dependant upon renal replacement therapy (Dialysis or 
Transplantation) in order to avoid life-threatening uremia52. 
 The close relationship between haematopoiesis and the kidney has been 
well recognized for over a century now.  Richard Bright in 1835 first described 
the association between anaemia and chronic renal failure.  Subsequent studies 
confirmed that erythropoiesis is inextricably linked to the kidney through its 
production of the hormone erythropoietin, the major regulator of red cell 
production by the erythroid marrow42.  Thus, any damage to the kidney which 
includes the cells responsible for the synthesis of erythropoietin and its 
physiological control, will cause a hypoproliferative anaemia, the severity of 
which closely parallels the degree of renal impairment.  In 1977 human 
erythropoietin was isolated and purified from urine of patients with aplastic 
anaemia (MIYAKE et al 1977).  This allowed cloning of gene for human 
erythropoietin (Lin et al 1985) which was then expressed in a suitable 
 4
mammalian cell line, making possible for the first time the largest scale synthesis 
of genetically engineered hormone47.  Clinical trials in haemodialysis began in 
Seattle and London towards end of 1985 (Winearls et al 1986; Eschbach et al 
1987).  It became licensed for use in renal anaemia in 1990. Much of the 
morbidity and mortality inherent in the renal failure patients can be attributed to 
the secondary consequences of chronic anaemia.  Other factors associated with 
chronic renal failure may contribute to the development of anaemia but 
erythropoietin deficiency is by far the major factor. 
 
NORMAL ERYTHROPOIESIS 
 
 The erythron is responsible for production of red cell mass of 30 + 5 ml/kg  
in males and 25 + 5 ml/kg in females and this is maintained by continual 
erythropoiesis.  Pluripotent stem cells which are capable of both self renewal and 
differentiation, under appropriate conditions including exposure to interleukin – 1 
gives rise to progenitor cells, committed to become myeloid, erythroid, lymphoid 
or megakaryocytic cells.  But differentiation of committed erythroid precursor 
into primitive erythroid progenitor cell, the ‘burst forming unit – erythroid’    
(BFU – E) is under influence of interleukin – 3 and granulocyte – macrophage 
colony stimulating factor (GM – MSF).  Multiplication and differentiation of the          
BFU – E and later ‘colony forming unit – erythroid’ (CFU – E) required the 
presence of erythropoietin52.  CFU – E is more sensitive to erythropoietin than 
BFU – E.  
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ACTION OF ERYTHROPOIETIN ON RED CELL PROGENITORS 
 Erythropoietin acts via specific receptors present on early red cell 
progenitors.  There are 500 to 1000 erythropoietin binding cytes per cell.  On 
binding, the receptor – erythropoietin complex internalizes and a variety of 
cellular response including a rise in intracellular calcium, increases in DNA and 
RNA synthesis, glucose uptake, globin gene expression, transferring receptor 
expression and finally haemoglobin synthesis occurs. Also occurs 
phosphorylation of a defined set of proteins which maintains the cellular viability 
of erythroid progenitors.  This crosses progenitor cells to procede with an 
endogenous programme of mitosis and terminal differentiation.  Erythropoietin 
also acts on receptors on endothelial cells causing a proliferative response, and 
stimulate thrombopoiesis possible due to structure homologies between 
erythropoietin and thrombopoietin, the megakaryocytic growth factor31. 
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ADDITIONAL FACTORS REQUIRED FOR NORMAL 
ERYTHROPOIESIS 
 
 The production of approximately 17 ml of red cells each day requires a 
number of additional factors including iron, folate, vitamin-B12, pyridoxine, 
ascorbic acid, thyroxine and various trace elements.  Of these iron is the most 
often identified to be deficient in patients both with and without renal failure31. 
 
IRON ABSORPTION AND METABOLISM 
 
 Most of the Iron in circulation is destined for haemoglobin synthesis.  It is 
transported in plasma bound to transferrin, a β – globulin, which binds to 1.3 µg 
of iron / mg of protein at two binding sites capable of binding two ferric atoms.  
Transferrin is synthesised in liver and its production is related to the amount of 
storage iron.  Under normal conditions, only 5 to 10% of dietary iron is absorbed, 
however, absorption can be modified according to iron requirements.  Iron that is 
in excess to cell requirements stimulates the synthesis of ferritin, a soluble 
protein which is capable of storing iron.  Thus, plasma ferritin concentration 
correlates well with iron stores.  Measurements of internal iron exchange are used 
to evaluate erythropoiesis.  The disappearance of transferrin bound Fe from the 
plasma is used to estimate the plasma iron turn over from which calculation for 
erythrocyte iron turn over, red cell utilization and marrow transmit time can be 
derived.  Recently more accurate estimate of active erythroid marrow – erythron 
 7
transferrin uptake based on plasma iron turn over has been developed.  This takes 
account of the extravascular flux of iron and the ratio of monoferric and differric 
transferrin, which differ in affinity for cell membrane receptors43. 
 
 
Normal haematological values in adults 
     Haemoglobin (g/dl) 
        Male 
        Female 
 
13.5 – 18 
11.5 – 16 
     Haematocrit  
        Male 
        Female 
 
0.40 – 0.54 
0.37 – 0.47 
     Red cell count (x 1012/1) 
        Male 
        Female 
 
4.5 – 6.5 
3.9 – 5.6 
     Mean cell volume (MCV) (fl) 81 – 100 
     Mean cell haemoglobin(pg) 27 – 32 
     Mean cell haemoglobin concentration (g/dl) 32 – 36 
     Reticulocyte count (%) 0.8 – 2.0 
     Absolute reticulocyte count (x 109/1) 25 – 100 
     Total blood volume (ml/kg) 70 + 10 
     Plasma volume (ml/kg) 45 + 5 
     Red cell volume (ml/Kg) 
        Male 
        Female 
 
30 + 5 
25 + 5 
     Erythron transferrin uptake (µmol/l.day) 60 + 12 
     Platelet count (x 109/l) 150 – 400 
     White cell count (x 109/l) 4.0 – 11.0 
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ERYTHROPOIETIN 
 
 History: In 1906, French scientists Carnot & Deflandere first suggested 
the existence of a humoral factor stimulating erythropoiesis.  In 1953, Ersley 
proved that transfusion of plasma from anaemic rabbits produced stimulation of 
erythropoiesis in recipient animals. Jacobson indicated kidney’s role in 
production of this erythropoietic substance.  In 1977, Miyake and co-workers was 
successful in purifying a few milligrams of this hormone.  Amino acids sequence 
information of this purified material provided the base for cloning of 
erythropoietin gene and its expression in mammalian cell lines45. 
 The kidneys and liver have been unequivocally identified as the 
predominant sites of erythropoietin production.  The controls of erythropoietin 
production have been identified to be regulated at the level of erythropoietin     
m-RNA and this regulation occurs predominantly via oxygen dependant control 
of transcription rate of erythropoietin39. 
THE STRUCTURE OF ERYTHROPOIETIN GENE AND 
MOLECULE 
 
 Gene encoding human erythropoietin is located on chromosome 7 and 
encompasses about 3000 base pairs.  It contains 5 exons and 4 introns and 
encodes for a 193 amino acid polypeptide.  A 27 amino acid sequence at the N 
terminal part and a carboxy – terminal arginine molecule are cleaved off during 
secretion leading to 165 amino acid mature protein.  Carbohydrate side chains 
which contributes 1/3 of molecular weight are necessary for both secretion and 
biological activity of hormone. 
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(a) Schematic presentation of transcription and translation of Erythropoietin 
(b) Three dimensional structure with disulphide bridges and carbothydrate side 
chains. 
 
MODE AND SITES OF ERYTHROPOIETIN PRODUCTION 
 
 Normal serum erythropoietin concentrations in humans are of the order of 
10 to 30 mU/ml as determined by radio immuno assays.  Assuming a mean serum 
half life of 5 to 9 hours, endogenous production of hormone, normally amounts to 
about 2 to 4 units / kg / day. 
 Erythropoietin concentration alters under a variety of conditions largely 
reflecting alterations of oxygen delivery to the tissues.  Anaemia, caused by 
bleeding or decreased red cell production is the most powerful stimulus for an 
increase in serum erythropoietin with an inverse relation between concentration 
of erythropoietin and haemoglobin concentration.  Inhalation of carbon 
monoxide, an increase in oxygen affinity of haemoglobin, reduction in arterial 
oxygen tension caused by either cardiopulmonary disorders or decrease in 
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oxygen tension of atmosphere are all important stimuli for erythropoietin 
secretion.  Hypophysectomy and starvation are associated with decreased 
concentration whereas stimulation by thyroxine increased  concentration of 
erythropoietin.  Thus, conditions of reduced oxygen supply and increased oxygen 
demand are accompanied by increased circulating erythropoietin concentrations 
whereas decreased concentration are typical of conditions with increased oxygen 
supply or reduced oxygen demand37. 
 Erythropoietin production has been showed to be primarily regulated by 
amount of erythropoietin m-RNA in liver and kidneys.  Liver is the predominant 
production site during fetal life whereas kidneys produce most of erythropoietin 
in adults. In addition, small amounts of erythropoietin m-RNA are found in brain, 
testis, lung and spleen. Erythropoietin production at these sites could have 
undefined paracrine effects. 
 In kidneys erythropoietin is produced in peritubular cells of renal cortex.  
These are fibroblast like cells which are located in the narrow inter spaces 
between tubules.  Cells in the cortical labyrinth, where convoluted portions of 
proximal and distal tubules are located and not in the medullary rays take part in 
erythropoietin production.  Even under severe hypoxia less than 20% of cortical 
fibroblast like cells in this location express erythropoietin and thus it is possible 
that only a yet unidentified sub group of specialized interstitial cells produces the 
hormone15. 
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OXYGEN SENSOR CONTROLLING ERYTHROPOIETIN 
PRODUCTION 
 
 These mechanisms are the key element in feedback control of 
erythropoietin production and are sensitive to: 
1. Conditions affecting arterial PO2 and consequently also tissue and 
venous PO2 (hypoxic hypoxia) 
2. Conditions in which arterial PO2 is normal and only tissue and venous 
PO2 are reduced. 
It is unlikely that arterial PO2 can directly influence erythropoietin 
production, rather it appears to be tissue oxygen tension that regulates hormone 
production.  With respect to renal erythropoietin production experiments with 
isolated perfused kidneys showed modulation of erythropoietin m-RNA and 
erythropoietin secretion in response to alterations of oxygen tension of the 
perfusate. 
 It has been showed that exponential increase in erythropoietin production 
in kidney that occurs with reduction in renal oxygen supply is primarily due to an 
increase in proportion of peritubular cells that express the erythropoietin gene 
and single cells respond in almost all – or – none man.  This recruitment occurs 
within cortical labyrinth and is directed from deep to superficial regions.  During 
chronic anaemia signs of morphological damage can be demonstrated in those 
areas where erythropoietin production occurs.  Low oxygen tension in the kidney 
cortex presumable results from both a restricted delivery of oxygen and high rate 
of oxygen consumption34.  The major reason for limited oxygen supply lies in 
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vascular architecture of the kidney where arteries and veins run in parallel over 
long distances and close contact between preglomerular arterial and venous beds 
allows oxygen to diffuse from arteries to veins long before blood reaches 
peritubular capillaries.  So, local tissue oxygen tensions can be much lower than 
in renal vein.  The major determinant of renal oxygen consumption is the 
transport work of nephron.  Since tubular reabsorption is proportional to amount 
of glomerular filtrate, and the glomerular filtration rate is proportional to renal 
blood flow, changes in renal blood flow influences both oxygen supply and 
consumption.  It doesn’t appears to have much influence in the ratio of both 
parameters.  This explains why kidney is able to adjust erythropoietin production 
to alterations to blood oxygen content with only a modest confounding influence 
from changes in renal haemodynamics35.  So, in renal artery stenosis incidence of 
erythrocytosis is low.  Among different nephron segments that contribute to renal 
oxygen consumption, the convoluted part of the proximal tubule seems to play an 
important role in erythropoietin regulation. 
CONTROL OF ERYTHROPOIETIN GENE 
 Accumulation of erythropoietin m-RNA in erythropoietin producing cells 
results mainly from an increase in transcription rate of gene, but a specific 
increase in stability of erythropoietin m – RNA may also contribute.  Of further 
importance for hypoxic induction of erythropoietin gene activity is a DNA 
sequence within the immediate 3’ flanking region of the gene39.  Activation of 
this enhancer during hypoxia is presumably mediated by a nuclear factor called 
‘hypoxia inducible factor 1’(HIF 1). 
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PATHOGENESIS OF ANAEMIA IN CHRONIC RENAL FAILURE 
CHARACTERISTICS OF ANAEMIA IN CHRONIC RENAL FAILURE 
 The peripheral blood film from a uraemic patient usually shows a 
normochromic normocytic anaemia, occasionally with fragmented red cells or 
burr cells.  The reticulocyte count is usually low for degree of anaemia although 
white cell count is usually normal31.  There may be reduced, normal, or increased 
cellularity of the bone marrow and the erythroid : myeloid ratio may be 
decreased.  But hyperplasia of the erythroid marrow is insufficient to compensate 
for anaemia present.  There is reduced red cell mass but normal total blood 
volume except in patients who are fluid overloaded.  Also a reduction in red cell 
life span contributes.  Factors suggested as contributors to the shortened red cell 
survival include blood loss, toxic haemolysis and hypersplenism.  The depression 
in erythropoiesis is explained by relative erythropoietin deficiency, the effect of 
uraemic inhibitors, iron or folate deficiency, aluminum toxicity, and marrow 
fibrosis resulting from hyperparathyroidism.   
IRON KINETIC STUDIES 
 In chronic renal failure serum iron, transferring, iron binding capacity, 
saturation and ferritin are usually normal.  Ferrokinetic studies in uraemic 
subjects show that iron – overloaded, transfusion – dependant patients have low 
erythron iron turnover and red cell iron incorporation, while non-iron loaded 
patients have near normal erythron iron turn over and a red cell utilization of 
iron43. 
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Ferrokinetics studies in anaemia 
 
Condition Haematocrit Red cell 
utilization 
(%) 
Plasma iron 
turnover 
(mg/dl.day) 
Erythron 
transferring 
uptake 
(µmol/l.day) 
Normal 
Haemodialysis       
    transfused 
Haemodialysis 
    non-transfused 
Haemolytic anaemia 
42 + 2 
23 + 3 
 
26 + 5 
 
27 + 5 
85 + 4 
26 + 10 
 
71 + 13 
 
72 + 19 
0.71 + 0.17 
0.73 + 0.16 
 
0.77 + 0.18 
 
3.86 + 1.45 
60 + 12 
35 + 11 
 
73 + 21 
 
400 + 130 
 
ERYTHROPOIETIN PRODUCTION DURING RENAL DISEASE 
END STAGE RENAL DISEASE:  Inability of erythropoietin production to 
respond to the degree of anaemia is independent of causal factors leading to end 
stage renal disease.  It can be due to destruction of erythropoietin producing cells 
or due to lack of appropriate signals that normally stimulate erythropoietin 
production10.  Further evidence indicate that ‘the oxygen – dependancy’ of 
erythropoietin formation is maintained in chronic renal failure, but that the 
system operates at a much a lower level of sensitivity than the intact kidney.  A 
reduction of tubular function contributes to inhibition of normal erythropoietic 
responds.  Also there may be inhibition by immuno modulatory cytokines.  
Increase in erythropoietin occurs in end stage renal disease as in response to 
acute blood loss, hypoxia, haemolysis and this possibly originate from extra renal 
sites.  
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POLYCYSTIC KIDNEY DISEASE:  Anaemia here is generally less severe 
than usual and occasionally patient may be polycythaemic2.  Also acquired renal 
cysts and single cysts may lead to erythrocytosis in haemodialysis patients.  
Serum erythropoietin concentrations in patients with autosomal dominant 
polycystic kidney disease are, on average, two fold greater than end stage renal 
disease of non-cystic origin.  In the cyst walls of patients autosomal polycystic 
kidney disease interstitial cells have been shown to express erythropoietin m – 
RNA, and cysts derived from proximal, but not those derived from distal tubules 
where found to contain increased concentrations of bioactive erythropoietin. 
RENAL ALLOTRANSPLANTATION:  Anaemia of end stage renal disease is 
usually reversed within three months of renal transplantation.  Within hours of 
transplantation, erythropoietin concentrations increase significantly and after few 
days plasma concentrations are reached that are, on average, about twice that 
before renal transplantation23.  10 to 17% of recipients develop polycythaemia 
after successful renal allotransplantation which in some cases appears to be due 
to inappropriately elevated erythropoietin production and in others due to 
increased sensitivity of erythroid progenitor cells to erythropoietin, or loss of  the 
feedback control mechanisms. 
RENAL ARTERY STENOSIS:  Renal erythropoietin production is rather 
insensitive to changes in renal blood flow.  The ratio of oxygen demand to 
oxygen delivery that governs erythropoietin production, and alterations of renal 
blood flow will, via a reduction in tubular sodium load, cause concordant changes 
of both parameters which tend to leave the ratio more or less unaltered. 
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RENAL TUMOURS:  Up to 5% of patients with renal carcinomas have 
erythrocytosis and 35% of those with tumour – associated erythrocytosis have 
renal cancer. Accumulation of erythropoietin m–RNA occurs in epithelial tumour 
cells but not interstitial cells of the tumour stroma. 
ERYTHROPOIETIN PRODUCTION AND DRUGS:  Acetazolamide reduces 
hypoxia induced elevations in zero erythropoietin and depending on the dose, this 
may be due to a decrease in pH which is known to suppress erythropoiesis or due 
to proximal tubular sodium transport inhibition.  Inhibition of erythropoietin is 
also seen after administration of angiotensin converting enzyme inhibitors. 
‘URAEMIC INHIBITORS’ OF ERYTHROPOIESIS 
 Substances suggested as inhibitors include polar lipids, arsenic, spermine 
and spermidine, vitamin A and parathyroid hormone.  But to date no inhibitors 
have been identified and if they exist are of minor importance. 
ROLE OF ALUMINUM 
 Aluminum overload is well know to cause dementia and bone disease 
which is becoming less common with better purifying of water for preparing 
dialysate.  Severe Aluminum overload in haemodialysis patients is associated 
with microcytic anaemia which improves when dialysate Aluminum is reduced 
by deionization of water supply or when aluminum overload is treated with 
desferrioxamine40. 
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IRON AND FOLATE DEFICIENCY 
 
 Haemodialysis patients have a small amount of blood loss during each 
dialysis.  In past with kiil dialysers a total yearly blood loss as high as 2.5 ltrs was 
reported.  These days blood loss amounts to between 4 and 20 ml / dialysis with 
additional loss from frequent blood sampling for haematological and biochemical 
measurements.  With normal iron loss from gastrointestinal tract, in the urine, or 
during menstruation in addition to loss during haemodialysis, a dialysis patient 
has a daily iron loss more than 2 mg43. Serum iron and transferring 
concentrations do not give an accurate guide to iron stores in chronic renal 
patients. Iron stores are best estimated by measurements of serum feritin 
concentrations, with concentrations less than 80 to 100 micro grams / litre 
suggesting iron deficiency 
 Iron reserves (mg) = 400 x [log (ferritin) – log (30)] 
 Staining of bone marrow for haemosiderin also gives a crude assessment 
of iron stores. 
 
 Folate is readily removed by haemodialysis.  So haemodialysis patients 
may require oral folate supplement.  Folate is not removed in significant amounts 
with peritoneal dialysis and dietary intake alone is usually sufficient.  Adequacy 
of folate stores is best estimated by red cell folate rather than serum folate. 
 
 
 18
HAEMOLYSIS 
 
 The moderately shortened red cell survival in uraemia appears to be 
related to blood urea concentrations.  Severe haemolysis is also associated with 
over heated dialysate, with several toxins including formaldehyde, copper, 
nitrates and chloramines.  Zinc toxicity also has been shown to cause anaemia16. 
 
INFLAMMATION 
 
 Infections and inflammatory conditions like surgery, pericarditis, 
vasculitis, malignancy, all reduce response of anaemia in renal failure to 
recombinant human erythropoietin.  Evidences suggest this is mediated by one or 
more inflammatory cytokines interacting with and inhibiting erythropoietin at 
cellular level.  TNF – α and γ interferon also are implicated. 
 
OTHER HAEMATOLOGICAL EFFECTS ASSOCIATED WITH  
CHRONIC RENAL FAILURE 
LEUCOCYTE ABNORMALITIES 
 
 A reduction in capacity of bone marrow to generate granulocytes has been 
documented in renal failure and there is an enhanced peripheral consumption of 
neutrophills by the dialyser in haemodialysis patients. Once glomerular filtration 
falls below 10 ml / minute, the phagocytic activity of leucocytes is impaired.  
Altered monocyte function with a reduced chemotactic response, reduced 
phagocytic activity and altered cytokine production occurs in uraemic patients.   
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Reduced production of IL – 2 by T cells and altered T lymphocyte function 
occurs in uraemia which is improved by high flux dialysis with poly sulphone 
membrane. This leucocyte abnormalities contribute to chronic immunodeficiency 
state characteristic of uraemia. 
 
PLATELET ABNORMALITIES 
 
 Defect in megakaryocytic lineage causes platelet abnormalities causing 
haemostatic problems characterized by prolonged bleeding type.  This appears to 
be due to a defect in activation of the glycoprotein adhesion receptors causing 
both impaired platelet aggregation and adhesion to the endothelium.  The mean 
platelet life span is reduced in uraemic patients.  This is corrected to normal after 
no less than 12 months treatment with regular haemodialysis.  The platelet 
membrane is affected by increased activity of oxygen free radicals in chronic 
renal failure and this is corrected by vitamin E.  The functional platelet defect of 
uraemia is reversed by a desmopressin or conjugated oestrogens intravenously 
possibly by release of Von Willebrand factor multimers from storage sites to 
plasms.  Oestrogen may also act by inhibiting vascular prostacyclins19.   
 
CLINICAL ASPECTS 
PREVALENCE OF ANAEMIA IN CHRONIC RENAL FAILURE 
 The majority of patients with chronic renal failure develop anaemia and 
this progressively increases in intensity as renal function deteriorate such that of 
patients starting dialysis only 3% have normal haematocrit. There is 
improvement after institution of dialysis, although up to 10% of patients become 
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blood transfusion dependant and many prior to advent of erythropoietin therapy 
required intermittent transfusion. Haemodialysis patients tend to have an increase 
prevalence of severe anaemia than continuous amulatory peritoneal dialysis.  
This is due to a greater degree of blood loss or haemolysis in haemodialysis 
patients, and better removal of erythropoietic inhibitory ‘middle molecules’ in 
CAPD patients.  The severity of anaemia in dialysis patients is independent of 
etiology of end stage renal disease with exception of patients with adult 
polycystic kidney disease who tend to have greater haemoglobin concentration26. 
 
PHYSIOLOGICAL CONSEQUENCES 
 
 Various physiological adaptations occur in an attempt to compensate for 
suboptimal oxygen delivery and these includes modulation of affinity of 
haemoglobin for oxygen, an increase in cardiac output, and redistribution of 
blood flow.  Symptoms and signs of anaemia include tiredness, lethargy, muscle 
fatigue, breathlessness at rest or exertion, angina, palpitations, increased 
sensitivity to cold, loss of appetite, loss of libido, menstrual irregularity, pallor, 
tachycardia, poor memory and concentration and impaired cognitive and 
neurophysiological function33. 
 
BLEEDING DIATHESIS 
 Chronic renal failure is associated with a bleeding tendency characterized 
by prolonged bleeding time.  Although uraemia results in various abnormalities 
of clotting factors and platelet function, the level of haematocrit is of 
considerable importance.  Correction of anaemia usually results in return of 
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bleeding time to normal.  This effect is seen both with transfusion and 
erythropoietin therapy.  The mechanism involved is poorly understood, but 
greater interaction of platelets with vessel wall, enhanced ADP production and 
improved platelet function may all play a role. 
CARDIOVASCULAR EFFECTS 
 Various adaptive cardiovascular mechanisms to compensate for reduced 
tissue oxygen delivery from anaemia occurs in chronic renal failure.  These 
include an increase in cardiac output, hypoxia induced peripheral vasodilation 
and compensatory increase in left ventricular mass causing ventricular 
hypertrophy.  This latter effect, along with concomitant coronary artery disease 
present in many renal patients, and the reduced oxygen carrying capacity of 
anemic blood, results in high incidence of myocardial ischemia and symptoms of 
angina36.  Other cardiovascular effects include an increase in left ventricular end 
diastolic dimensions, impaired myocardial contractility, and both systolic and 
diastolic dysfunctions.  As a result, exercise capacity of patients with chronic 
renal failure is severly impaired, as are measures of respiratory physiology such 
as maximum oxygen consumption, anaerobic threshold and diffusion capacity of 
the lungs.  Many of these effects are reversed by correction of anaemia with 
transfusion erythropoietin therapy or renal transplantation.   
IMPACT OF HAEMATOCRIT ON MORBIDITY AND MORTALITY  
 Recent large epidemiological studies have shown that mortality and 
morbidity are reduced when the hematocrit level is in the range of 33 to 36% and 
the National Kidney Foundations Dialysis Outcomes Quality Initiative 
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(NKFDOQI) recommends this target42.  The recent mortality studies show that 
hematocrit less that 30% are associated with an 18 to 40% increased associated 
risk of death and hospitalization compared with patients with hematocrits of 30% 
to less than 33%.  Patients with sustained hematocrits of 33% to 36% over one 
year appear to have the best outcome compared with patients with less 
hematocrits. 
MANAGEMENT OF ANAEMIA 
ASSESSMENT OF KIDNEY FUNCTION 
 Although GFR is considered the most accurate measure of renal function, 
it is difficult to measure in clinical practice because it requires a radioisotope and 
a precisely timed urine collection.  Creatinine clearance measurements with 
timed urine collections provide a reasonable estimate of GFR. 
 Clinicians most commonly use SCr concentration as an indicator of level 
of kidney function.  However, SCr is affected by factors other than GFR, such as 
age, gender, race, muscle mass, nutrition and meat intake.  With progressive loss 
of kidney function, there is often reduced creatinine generation related to loss of 
muscle mass, malnutrition, and restricted meat intake, and the increased tubular 
secretion and extra-renal excretion of creatinine with advancing renal 
dysfunction46.  Consequently, SCr levels and CrCl can underestimate the severity 
of kidney dysfunction.  In this situation, the average of the creatinine and blood 
urea nitrogen (BUN) clearances with a 24-hour collection more closely 
approximates GFR. 
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 Cockroft – Gault equation makes out creatinine clearance from serum 
cratinine values. 
 
 
 African-American study of Kidney Disease and Hypertension and the 
Modification of Diet in Renal Disease (MDRD) study equation is as follows: 
 
 
 
 
 
ASSESSMENT OF ANAEMIA 
 
 The NKF published recommendations in 1997, which were updated in 
2000, for the management of anaemia among patients with CKD and ESRD.  The 
NKF has recently proposed guidelines for the evaluation of anaemia among 
patients with CKD10.  The guidelines for evaluation recommend that patients with 
a GFR of < 60 mL/min/1.73m2 should be screened for the presence of anaemia 
by obtaining a HCT and Hgb.  A complete anaemia work-up should be initiated if 
the HCT is <33% or the Hgb is <11 g/dL in premenopausal females and 
prepubertal patients or if the HCT is <37% or the Hgb is <12 g/dL in 
postmenopausal females and adult males.  Evaluation of anaemia should consist 
of measurements of at least the tests listed in Table prior to the initiation of r-
HuEPO therapy. 
CrCl (in mL/min) = 140 – age) x ideal body weight in kilograms / SCr 
in mg/dL x 72 (multiply by 0.85 for women) 
GFR (in mL/min/1.73 m2 = 170 x [serum creatinine (mg/dL)] -999 x [age 
(years)] -176 x [0.762 if female] x [1.180 if black] x [blood urea nitrogen 
(mg/dL)] -170 x [albumin (g/dL)] +318 
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EVALUATION OF ANAEMIA AMONG PATIENTS WITH CKD 
Complete blood count with red blood cell indices  
Reticulocyte count 
Iron studies 
     Serum iron 
     Total iron binding capacity (TIBC) 
     Percent transferrin saturation (serum iron x 100/TIBC) 
     Serum ferritin 
Occult blood in stool 
 
OTHER CAUSES OF ANAEMIA 
 The possibility of other causes of anaemia among CKD patients must also 
be considered.  It is particularly important to search for nutritional deficiencies 
among elderly patients, as the prevalence of iron, vitamin B12, or folate 
deficiency is higher compared with younger individuals43. In addition, 
deficiencies in L-carnitine, vitamin B6, ascorbic acid and vitamin D may 
contribute to anaemia.  Supplementation with L-carnitine in hemodialysis 
patients appears to improve the response to r-HuEPO, reduce erythrocyte fragility 
among hemodialysis patients, and decrease r-HuEPO requirements among 
patients with CKD.  However, supplementation with vitamins C, D, B6, B12 and 
folate is considered of potential benefit in the hemodialysis population.  In 
patients who are diagnosed as being iron-deficient, iron stores should be 
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monitored every 1 to 3 months to assess adequacy of treatment. This is especially 
important in the patient being treated with r-HuEPO who is not receiving IV 
iron46. 
POTENTIAL CONTRIBUTORS TO ANAEMIA IN PATIENTS WITH 
CHRONIC KIDNEY DISEASE 
     Nutritional deficiencies 
           Iron 
           Vitamins (vitamin C, D, B6, B12 and folate) 
            L-Carnitine 
     Chronic inflammation or infections 
     Secondary hyperparathyroidism 
     Aluminum bone disease 
     Chronic blood loss or hemolysis (hemoglobinopathy) 
     Bone marrow suppression by medications 
     Bone marrow malignancy 
     Angiotensin converting enzyme (ACE) inhibitors 
     Advancing kidney failure with accumulation of toxins normally cleared by  
     Kindneys 
 
 The impact of factors related to CKD, or factors that may develop with 
advancing uremia, must also be considered in both the initial and ongoing 
evaluation of anaemia.  These include the cause of the CKD, use of angiotensin-
converting enzyme (ACE) inhibitors and secondary hyperparathyroidism.  Once 
treatment has begun, inflammatory conditions and chronic infections may result 
in r-HuEPO resistance. 
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 The use of ACE inhibitors is well known to result in anaemia and can also 
result in increased r-HuEPO dose requirements.  Thus, among patients with 
advanced CKD, in whom there is no longer a significant role for ACE inhibitors 
to delay progression to ESRD, discontinuation of ACE inhibitors should be 
considered if there is no other pressing indication for use. 
 Secondary hyperparathyroidism may lead to bone marrow fibrosis and to 
reduced response to r-HuEPO, and thus must be considered even among patients 
with a fairly modest degree of renal dyusfunction50.  Although uncommon in 
earlier phases of CKD, aluminum bone toxicity can occur among patients taking 
aluminum-containing antacids, and this possibility should also be expolored.  
Finally, advancing uremia may result in worsening anaemia and increasing           
r-HuEPO requirements and may signal the need to consider dialysis or 
transplantation. 
OPTIMAL TARGET HAEMOGLOBIN 
 Ideally target haemoglobin should be individualized.  An opinion poll of 
European nephrologists and NKF – DOQI guidelines currently recommend a 
target haemoglobin of 11 to 12 gm/dl. 
The rationales for these target levels are: 
1. The level of 33% is just below the lower limit of normal for 
premenopausal females, and 36% is just below the lower limit of normal 
for males and postmenopausal females. 
2. Worse outcomes have been reported when the HCT is below 30% to 33% 
(with Hgb 10 – 11 g/dL). 
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3.  Improvement of HCT results in improvement in LVH. 
4. Patients function better with higher HCT levels. 
HAEMATINIC SUPPLEMENTS 
 Patients with chronic renal failure are prone to develop a haematinic 
deficiency state as a result of dietary restrictions, poor appetite and increased 
blood loss.  Such patients are screened for iron, vitamin B12 and folate 
deficiencies and supplements are given as required. 
 Iron deficiency anaemia can develop relatively early in the course of 
chronic renal failure43.  The clinical practice guidelines for the treatment of 
anaemia in chronic renal failure, established in the United States by the National 
Kidney Foundation-Dialysis Outcomes Quality Initiative and in Canada by the 
Canadian Society of Nephrology, recommend the use of intravenous (IV) iron 
therapy for iron supplementation in hemodialysis patients, most patients on 
peritoneal dialysis, and some predialysis patients once the patient’s serum ferritin 
falls below 100 ng/mL or transferring saturation below 20%.  Furthermore, 
effective iron replacement and maintenance play a vital role in efficient use of 
recombinant erythropoietin. 
 For hemodialysis patients, IV iron has proven convenient and such 
patients may require supplementation with parenteral iron in excess of 1000 mg 
to achieve optimal response in hemoglobin/hematocrit (Hgb/Hct) levels.  With 
regard to oral iron, patient compliance has been hindered by patient discomfort 
when taking such medication.  However, patients on peritoneal dialysis and those 
with chronic kidney disease remain good candidates for oral iron because of  
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convenience.  Some authors doubt the effectiveness of oral iron replancement, as 
absorption may be reduced in the uremic state especially in those patients taking 
concomitant phosphate binders.  The proof is in the pudding, however, and 
therefore response to iron therapy should be monitored regularly.  If the ferritin 
and transferring saturation does not improve to the recommended level, then 
supplement intravenous iron should be used1. 
DOSE AND ROUTES OF IRON ADMINISTRATION 
 There are multiple possible dosing regimens for parenteral iron, which 
have been shown to be safe and effective in patients with CKD.  Doses studied 
have included 200 mg infusions monthly for 5 months and total dose infusions of 
up to 1600 mg. 
DIALYSIS 
 An improvement in anaemia is seen some patients during the first few 
months after starting dialysis and this may be related to the intensity of dialysis 
treatment and to an enhanced red cell survival5.  The improvement in 
haemoglobin concentration is greater with CAPD than with haemodialysis 
initially, but three years of treatment, there is little difference between the two 
modalities.  Plasma erythropoietin concentrations are decreased or unchanged 
during initiation of dialysis suggesting that other mechanisms may be involved. 
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ANDROGEN THERAPY 
 
 Androgens increase erythropoiesis by stimulating endogenous 
erythropoietin production.  They are beneficial only in mild cases under limited 
by high insulin of side effects such as virilization, muscle and liver damage and 
cholestasis49. 
 
BLOOD TRANSFUSION 
 
 Before advent of erythropoietin many chronic renal failure patients 
required repeated blood transfusions to avoid complications of severe anaemia.  
This has several disadvantages like: 
 
1. Suppression of residual endogenous erythropoietin production and 
hence erythron activity. 
 
2. Iron overload and tissue iron accumulation. 
 
3. Risk of infections from blood borne viruses like hepatitis B & C, 
CMV, HIV. 
 
4. Transfusion exposes patient to a wide range of HLA antigens, 
resulting in cytotoxic antibody production which renders successful 
renal transplantation less likely by reducing the chance of obtaining a 
negative cross match52. 
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ERYTHROPOIETIN THERAPY 
 
 Although the aetiology of renal anaemia is multifactorial, by far the major 
factor is a relative deficiency of erythropoietin produced by diseased kidneys.  
Thus, circulating concentration of the hormones is always inappropriately low for 
the degree of anaemia45.  Recombinant human erythropoietin was licensed for 
human use in 1990 which is one of the greatest advances in clinical nephrology in 
recent years. 
 
PHARMACOKINETICS 
 
 Recombinant human erythropoietin is inactivated by acid in stomach and 
therefore needs to be given parenterally.  The early trials in haemodialysis 
patients used intravenous erythropoietin administered thrice weekly.  Since then 
intraperitoneal, subcutaneous, intradermal routes of administration have been 
investigated (Boelaert et al 1989; Macdougall et al 1989).  After intravenous 
administration serum erythropoietin concentrations decay monoexponentially, 
with elimination half life of 4 to 11 hours (Macdougall et al 1991).  Some trials 
found that half life is shortened with repeated administrations.  With 
intraperitoneal  administration peak concentrations are 2 to 5% of intravenous 
dose and bioavailability is low at 3 to 8%. 
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 With subcutaneous administration peak serum concentrations of about 4 to 
10% of an equivalent intravenous dose are obtained at 12 hours, and thereafter 
they decay slowly such that concentration greater than baseline are still present at 
4 days.  The bioavailability of subcutaneous erythropoietin is about 7 times of 
intraperitoneal administration47. 
THE RENAL ANAEMIA MANAGEMENT PERIOD (RAMP) 
 
 The high prevalence of anaemia and the historically infrequent use of         
r-HuEPO for its treatment prior to ESRD, despite the increasing recognition of 
the association of anaemia with outcomes among patients on dialysis, leads to the 
realization that anaemia is underrecognized and undertreated among patients with 
CKD.  The concept of a “renal anaemia management period” or “RAMP” was 
developed to highlight the period of progressive loss of kidney function during 
which anaemia and other complications of kidney disease develop.  During this 
period, which begins with the establishment of progressive loss of kidney 
function and varies in duration based on rate of loss of kidney functionand other 
comorbid conditions, there is an opportunity to intervene with specific measures 
to control anaemia and the other expected complications of CKD14.  Treatment of 
anaemia and other complications should lead to decreasing the impact of 
associated comorbid conditions.  Conversely, failure to treat anaemia and other 
complications may lead to more adverse outcomes.  The operative word in the 
term RAMP is ‘management’.  This refers to proactive intervention to control 
very treatable conditions. 
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HAEMATOLOGICAL EFFECTS 
 Approximately 90 to 95% dialysis patients treated with erythropoietin 
respond with an improvement in their anaemia.  On regular therapy an increase in 
reticulocyte count of 2 to 3 times the baseline is evident at week 1 and increase in 
haemoglobin concentration is seen at 3 weeks.  The optimum target haemoglobin 
is around 10 to 12 gram / dl after 4 to 6 months of therapy.  There is usually a 
decline in serum ferritin and serum transferrin saturation following 
commencement of erythropoietin therapy43.  Radio isotopic blood volume studies 
show an increase in red cell mass and compensatory reduction in plasma volume 
such that whole blood volume remains unchanged.  Ferrokinetic studies indicate 
two-fold increase in marrow erythropoietic activity.  There is no change in mean 
red cell life span. 
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FACTORS AFFECTING RESPONSE TOERYTHROPOIETIN  
 
 Patients with more severe anaemia at onset of treatment generally require 
greater doses.  Functional iron deficiency has become increasingly apparent in 
patients on erythropoietin therapy.  Many individuals who are iron replete at start 
of treatment become deficient under influence of erythropoietin and require 
intensive iron supplementation39. 
 Dialysis patients often have increased occult gastrointestinal blood loss, 
partly due to greater prevalence of gastritis, peptic ulceration and partly due to 
increased bleeding tendency due to uraemic platelet dysfunction and heparin 
administration during dialysis.  Presence of acute of chronic infection, 
inflammatory disease or malignancy frequently causes marked inhibition of 
response to erythropoietin. 
 
SECONDARY EFFECTS OF ERYTHROPOIETIN 
 
 In view of the high cardiovascular mortality among ESRD patients, the 
prognostic significance of LVH in ESRD, the relationship between LVH and 
advancing CKD, the role of anaemia in the development of LVH, and evidence 
that correction of anaemia results in regression of LVH, it would appear that 
early correction of anaemia with r-HuEPO would result in improved long-term 
clinical outcomes36.  Although there are no controlled clinical studies among 
patients with CKD to confirm this hypothesis, 2 lines of indirect evidence support  
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the premise that correction of anaemia of CKD with r-HuEPO could result in 
decreased cardiovascular morbidity and mortality.  First, it has been shown that 
treatment that reduces LVH reduces mortality among patients with essential 
hypertension.  Second, studies in ESRD patients have shown an association 
between higher HCT and hemoglobin (Hgb) levels and a reduced risk of 
hospitalization and mortality.  Consequently, available evidence supports early 
treatment of anaemia among CKD patients. 
 Noncardiac benefits of treatment of anaemia of CKD have also been 
demonstrated.  Revicki and coworkers found that patients in the group targeted to 
achieve HCT levels > 36% (achieved by 79% of subjects) had significantly 
improved QOL compared with untreated controls whose mean HCT was 26%.  In 
addition, the United States Recombinant Human Erythropoietin Predialysis Study 
documented improved QOL as HCT levels increased about 30%. 
 
Cardiovascular System 
 
 Longstanding anaemia has profound effects on cardiovascular system 
many of which are reverse or improved during erythropoietin therapy.  There 
occurs normalization of cardiac output, reversal of vasodilation, increase in mean 
arterial pressure, improvement in oxygen delivery to myocardium and reduction 
in ventricular mass.  The latter is important as ventricular hypertrophy is an 
independent determinant of survival in dialysis patients (Silberberg et al 1989)36. 
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Cardiovascular effects of erythropoietin therapy 
   Increased exercise tolerance  
   Normalization of elevated cardiac output 
   Increased peripheral vascular resistance 
   Increased blood pressure (30 per cent of patients) 
   Decreased symptoms of angina 
   Reduction in myocardial ischaemia 
   Reduction in left ventricular hypertrophy 
   Reduction in left ventricular internal dimensions 
   Decreased cardiac size on chest radiograph 
 
 
Non cardiovascular effects  
 
 Studies on coagulation and haemostatic pathways shows improvement of 
aggregation and adhesion of platelets.  A prothrombotic state may develop due to 
increased blood viscocity, reduced protein C and protein S levels, increased 
thrombin – antithrombin levels and PAI – 1 production. 
 Erythropoietin induced increase in red cell mass increased haematocrit and 
blood viscocity21. Patients report subjective improvement in memory 
concentration and other cerebral functions following erythropoietin therapy.  
Electrophysiological studies shows an increase in amplitude of P3 component of 
brain event – related potential and a higher score in various neuropsychological 
tests.  Levels of cytotoxic antibodies decline following erythropoietin therapy and 
phagocytic function of neutrophils improve.  Nutritional status of patients treated 
with erythropoietin also improves. 
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  Non-cardiovascular effects of erythropoietin therapy 
   Improved quality of life 
   Improved brain/congnitive function 
   Decreased uraemic bleeding tendency 
   Improved platelet function 
   Improved sexual function 
   Improved endocrine function 
   Enhanced immune function 
   Decreased uraemic pruritus 
 
  
ADVERSE EFFECTS 
 Hypertension is the most common and troublesome occurring 
approximately in 20 to 30% of those patients treated.  The risk increases with 
previous history of hypertension, the rate of increase of haematocrit or target 
haemoglobin achieved. 
 
Adverse effects of erythropoietin therapy 
   Hypertension 
   Seizures / encephalopathy 
   Vascular access thrombosis 
   Clotting of dialysis lines 
   Hyperkalaemia 
   Myalgia / Influenza like symptoms 
   Skin irritation    
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 In most instances, blood pressure is easily controlled by fluid removal and 
use of standard antihypertensives20. 
 
 Several studies in humans have shown no significant acceleration of 
progression of kidney disease by correction of anaemia with r-HuEPO, provided 
that blood pressure control is adequate. 
 
Factors inhibiting response to erythropoietin therapy 
   Major                                                Minor          
   Iron deficiency                                 Hyperparathyroidism 
                                                             (with marrow fibrosis) 
   Blood loss                                         Aluminum toxicity 
   Infection/Inflammation                    Vitamin B12/folate deficiency 
                                                             Haemolysis 
                                                             Marrow disorders 
                                                             Haemoglobinopathies 
                                                             Underdialysis 
                                                             Carnitine deficiency 
                                                             ACE-inhibitors 
                                                             ? Erythropoietin antibodies 
 
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN (NESP) 
 
 NESP is a hyperglycosylated analogue of recombinant human 
erythropoietin which stimulates erythropoiesis in an identical manner to              
r-HuEPO.  But it has an increased sialic acid-containing carbohydrate content, 
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making it biochemically distinct from r-HuEPO34.  An increased amount of sialic 
acid-containing carbohydrate has been associated with increased serum half life 
and greater invivo biological activity.  So its terminal half life after IV 
administration is 3 fold longer than for IV rHuEPO.  This allows injection for 
both IV and subcutaneous NSEP to be given less frequently i.e., once weekly or 
even once every other week.  The optimum starting dose is 0.45 microgram/kg 
once weekly. 
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MATERIALS AND METHODS 
 
SELECTION AND ENROLEMENT OF CASES 
 
1.  INCLUSION CRITERIA 
 a.  All patients should be diagnosed cases of chronic renal disease with  
      anaemia. 
b. None of the patients should have received erythropoietin therapy 
c. Patients should not be having other significant systemic involvement 
other than due to uraemia 
2.  EXCLUSION CRITERIA 
 Patients having any contraindications as per inclusion criteria shall be 
excluded from the study. 
3.  DATA COLLECTION 
 Simple proforma containing details of patients will be filled up.  The 
following biochemical parameters were assessed as follows: 
 Haemoglobin: cyanmeth method 
 Serum creatinine: alkaline picrate method 
 Feritin: antiferritin labeled with lodine 125 
 TIBC: Incubating with serum ferric ammonium citrate 
 Protein: Biuret method 
 Albumin: using bromocresol green 
 Cholesterol: Enzymatic colourimetric test 
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 Alkaline phosphatase: p-nitro phenol phosphate 
 Cholesterol: Enzymatic colourimetric test 
 Alkaline phosphatase: p-nitro phenol phosphate 
 Phosphorous: Molydate u.v. method 
 Stoll occult blood: Guaic test 
 Uric acid: Spectrophotometric uricase/peroxidase 
4.  STUDY DESIGN 
 This will be a cross-sectional study of patients with chronic renal disease 
and anaemia chosen from Department of Nephrology based on the criteria from 
January 2008 to August 2008.  We propose to study 50 cases of hospital 
admission for minor ailment (e.g. viral fever) as controls. 
 
STATISTICAL CONSIDERATIONS 
 The collected data will be statistically analysed.  The end point of the 
study will be completion of analysis of the data. 
 
CORROBORATING DEPARTMENT 
1. Department of Medicine, Stanley Medical College, Chennai 
2. Department of Nephrology, Stanley Medical College, Chennai 
3. Department of Community Medicine, Stanley Medical College, 
Chennai 
4. Department of Biochemistry, Stanley Medical College, Chennai 
5. Department of Pathology, Stanley Medical College, Chennai 
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OBSERVATIONS 
 
SAMPLE SIZE 
 50 cases of chronic renal disease were studied.  The observations made in 
the study were as follows. 
SEX DISTRIBUTION 
 Out of 50 patients, 14 were females and the remaining 36 males. 
 
 
AGE DISTRIBUTION 
 Age distribution ranged from 15 years to 77 years.  The variation is from 
15 to 77 years in males and from 16 to 56 years in females. 
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 Mean age of females was 41 and that of males was 47. 
 
NATURE OF RENAL DISEASES 
 Intrinsic renal diseases leading to renal failure were numerous of which 
diabetic nephropathy was the most common. 
 
 
 
 
 
 
 
 
 
 
 44
Hb values ranged from 4.7 to  10.6 g/dl with a mean value of 7.46 g/dl. 
 
Serum creatinine: 
Values ranged from 1.9 mg% to 13.9 mg% with a mean value of 5.6 mg%. 
 
Serum Albumin: 
Values ranged from 1.80 g/dl to 4.80 g/dl with a mean value of 3.6 g/dl. 
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Total protein: 
Values ranged from 3.80 g/dl to 7.20 g/dl with a mean value of 6.2 g/dl. 
Stool occult blood: 
 
Serum cholesterol: 
Values ranged from 110 mg% to 324 mg% with a mean value of 183 mg%. 
Serum Alkaline phosphatase: 
Values ranged from 81.4 IU to 743.0 IU with a mean value of 238 IU. 
Serum Calcium: 
Levels vary from 6.4 mg% to 12.0 mg% with a mean value of 9.1 mg%. 
Serum Phosphorus: 
Levels vary from 2.5 mg% to 15.1 mg% with a mean value of 5.2 mg%. 
Serum Uric Acid: 
Levels vary from 3.0 mg% to 10.5 mg% with a mean value of 7.2 mg%. 
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Serum Ferritin: 
Levels vary from 130µg% to 1042 µg% with a mean value of 403.6 µg%. 
Peripheral smear 
 Most frequent picture was normochronic normocytic.  Also noted were 
dimorphic, normocytic hypochromic and microcytic anaemias. 
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PARTIAL CORRELATION COEFFICIENTS 
Controlling for AGE 
 HB S.CREATININE 
HB 1.0000 
(0) 
-.3115 
(38) 
S.CREATININE -.3115 
(38) 
1.0000 
(0) 
 
P = .050 
(Coefficient / (D.F.) / 2 tailed Significance) 
 
 
 
PARTIAL CORRELATION COEFFICIENTS 
Controlling for Hb 
 S.CREATININE S.PHOSPHORUS 
S.CREATININE 1.0000 
(0) 
.4569 
(27) 
S.PHOSPHORUS .4569 
(27) 
1.0000 
(0) 
 
P = .013 
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Controlling for HB 
 S.CREATININE S.FERRITIN 
S.CREATININE 1.0000 
(0) 
.9554 
(2) 
S.FERRITIN .9554 
(2) 
1.0000 
(0) 
 
P = .045 
 
 
 
Controlling for Hb 
 S.CREATININE S.CHOLESTEROL 
S.CREATININE 1.0000 
(0) 
-.4563 
(35) 
S.CHOLESTEROL -.4563 
(35) 
1.0000 
(0) 
 
P = .005 
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DISCUSSION 
 
 In this study we have anaylsed 50 patients with chronic renal failure and 
having anaemia of whom 14 were females.  Age of patients ranged from 15 to 77 
years.  Mean age of males was 47 years and that of females was 41 years.  The 
mean hemoglobin level in males was 7.4 g% and that in females was 7.7 g%.  
None of them had prior treatment with erythropoietin for anaemia.  All were 
excluded of having other serious systemic disorders.  Few were on treatment with 
hemodialysis.  All the patients were selected from Nephrology Department, 
Stanley Medical College and Hospital, Chennai-1. 
 Etiology for renal disease in our patients varied, most common being 
diabetic nephropathy which accounted from 28.6% cases.  This is well in 
correlation with other world wide studies.  Other important etiologies included 
chronic glomerulonephritis (22.2%), ADPKD (15.8%), Chronic tubulointerstitial 
disease (13.3%), IgA nephropathy (11%) and obstructive uropathy (6%).  
Hypertension, which is one of the commonest etiologies of CRF was not singly 
found as an etiological factor in our study, even though poorly controlled 
nypertension was present in a significant number of patients.  This may be 
because only few of our patients underwent renal biopsy to have histological 
evidence for etiology.  Also small sample size may be a factor for deviation from 
the general.  In our study also ADPKD was the commonest etiological factor 
with monogenic inheritance. 
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 Most of them in the study were having symptomatic moderate renal 
insufficiency.  The commonest symptoms noted in our study were those due to 
mild anaemia, recurrent infections, loss of energy, decreased appetite, nocturia 
and early disturbance of nutritional status. 
 A significant inverse correlation was noted between serum creatinine and 
hemoglobin indicating that the severity of anaemia increases with renal failure.  
Other variables chosen for the study including stool occult blood (as marker for 
gastrointestinal blood loss), total protein, serum albumin, serum cholesterol (as 
indicators of nutritional status), Alkaline phosphatase, serum calcium or serum 
phosphorus and serum uric acid were not singly found to influence significantly 
this relation.  Study population showed striking inter individual variability in 
progression to end stage renal disease irrespective of underlying etiology.  Also it 
was noted that clinical symptom of uraemia were poorly correlating with elevated 
level of uraemic toxins. 
 One of the patients with a positive stool occult blood had third degree 
hemorrhoids for which local banding and hematinics were given improving her 
anaemia.  Two thirds of those with stool occult blood positive had microcytic 
hypochromic anaemia.  Since these patients have additional gastrointestinal blood 
loss and iron deficiency, correction of these with blood transfusion and iron 
supplementation will be the first treatment option when comparing the cost 
effectiveness of erythropoietin therapy.  In our community since malnutrition is 
more prevalent, correction of anaemia with iron supplementation should be more 
effective than those proven western results. 
 51
 Vast majority of the study population had normochromic normocytic 
blood picture in peripheral smear which is consistent with other well established 
studies.  This proves that erythropoietin deficiency is the single most important 
causative factor of anaemia.  The rest were having either microcytic 
hypochromic, dimorphic or normocytic hypochromic anaemia indicating 
associated blood loss, malnourishment or dialysis induced anaemia.  Another 
significant observation was that the mean haemoglobin values in those with 
normochromic normocytic anaemia was significantly higher than that of those 
with other forms of anaemia indicating the presence of additional aetiologies like 
G.I. blood loss as indicated by positive stool occult blood, iron decifiency or 
malnutrition.  Correction of these factors should improve the anaemia, and the 
symptoms and morbidity causes by it to a great extent.  Erythropoetin therapy 
consists of twice weekly doses of 2000 IU for 6 to 8 weeks to achieve a target Hb 
level of at least 10 gm%.  Thereafter, maintenance dose of 2000 IU is required 
once weekly.  Each dose costs at least Rs.500/- and the therapy is to be continued 
life long.  Concomitant parenteral iron therapy with once weekly elemental iron 
injections is mandatory.  As most of the patients belong to low socio-economic 
strata and cannot afford life long erythopoetin therapy, correction of other 
causative factors would be a feasible approach in relieving their misery. 
 Significant inverse relation was found between serum cholesterol and 
serum creatinine levels indicating malnourishment in uremia.  Relationship was 
also noted between serum creatinine and serum ferritin.  This unexpected result 
can be attributed due to multiple blood transfusions received by those patients 
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with high ferritin.  Serum creatinine and serum phosphorus levels also showed a 
direct relationship denoting the divalent ion metabolic abnormality of uraemia.  
Such a relationship was not met with S.Calcium and S.Creatinine, may be due to 
interference with frequent calcium and vitamin D supplementation. 
 
 Dialysis as a mode of treatment in renal disease improves the uremic 
milieu and is supposed to improve anemia also.  But as dialysis can cause blood 
loss worsening anemia by: 
 
1. Blood loss through tubings 
2. Blood retention in the dialyser 
3. Water treatment defects 
4. Presence of chloramines in treated water 
5. Multiple venepunctures 
6. Temperature alterations leading to haemolysis 
 
This may be the cause of anemia out of proportion to other uremic 
indicators in some of our patients who underwent dialysis.  Additional factors 
causing anemia includes iron deficiency, blood loss from repeated lab tests, 
gastro intestinal bleeding usually from colitis, hyperparathyroidism, acute and 
chronic inflammatory conditions, Aluminum toxicity, folate deficiency, 
shortened red cell survival, hypothyroidism and rarely from underlying 
hemoglobinopathies. 
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Total protein, serum albumin and serum cholesterol are expected to be 
reduced in renal disease in proportion to reduction of haemoglobin.  But such a 
relation was not met in this study.  This may be accounted either by use of 
hemodialysis in some patients, multiple blood transfusions received by some of 
our patients or due to small study population. 
 
 Calcium and phosphorus are the major divalent ions involved in metabolic 
abnormalities of chronic renal diseases.  High values of serum ferritin noted in 
some of our patients can be attributed to multiple blood transfusions received by 
them.  The established inverse relation between serum uric acid and hemoglobin 
was not significantly proved, probably due to small sample size of the study.  
S.Sodium levels was not a chose variable among electrolyte profile since in 
chronic renal disease either sodium retention, wasting or maintenance of sodium 
balance can occur. 
 
 Since this study takes into consideration, only a small sample population, 
the results obtained from this study is to be confirmed by further larger studies. 
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CONCLUSIONS 
 
This study indicates that: 
 
1. Severity of anemia correlates well with the degree of renal disease. 
 
2. Normochromic normocytic morphology anemia caused by 
erythropoietin deficiency is by far the commonest pattern. 
 
3. Other morphologies in peripheral smear usually indicates presence of 
additional risk factors for anemia like blood loss, iron deficiency and 
malnutrition. 
 
4. Presence of such risk factors is associated with significant reduction in 
mean haemoglobin values. 
 
5. This suggests need for treatment of iron deficiency and correction of 
other anaemic risk factors in chronic renal disease. 
 
6. Diabetic nephropathy is the commonest aetiology of chronic renal 
failure. 
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PROFORMA 
 
 
NAME  AGE   SEX   IP/OP No. 
 
ADDRESS     OCCUPATION 
 
 
 
  
PRESENTING COMPLAINTS 
1. 
2. 
3. 
H/O. PRESENTING COMPLAINTS 
 
 
PAST HISTORY 
 
GENERAL 
 
H/O RENAL DISEASE 
 
H/O TREATMENT TAKEN (including DIALAYSIS and TRANSFUSIONS) 
 
HISTORY S/O ANAEMIA 
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PHYSICAL EXAMINATION 
GENERAL EXAMINATION 
  Built and Norishment 
  Pallor 
  Skin 
  Nails 
  Oedema 
  Pulse rate 
  B P 
  J V P 
  Respiratory rate 
  Temperature 
  Eyes, Oral cavity 
  Asterixis 
EXAMINATION OF 
 ABDOMEN   
  Skin changes 
  Palpable mass 
  Ascitis 
  Rectal examination 
  Renal bruit 
 CARDIOVASCULAR SYSTEM 
  Cardiomegaly 
  Added heart sounds 
  Arrhythmias 
  Basal crackles 
  Evidence of pericarditis 
  Vascular bruit 
 RESPIRATORY SYSTEM 
  Kussmaul’s breathing 
  Additional sounds 
  Pleural effusion 
 CENTRAL NERVOUS SYSTEM 
  Evidence of uraemic encephalopathy 
  Evidence of peripheral neuropathy 
  Complication due to hypertension 
  Optic fundii 
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 HAEMATOLOGICAL SYSTEM 
  Evidence of defective coagulation 
 WATER AND ELECTROLYTE IMBALANCE 
  Evidence of fluid overload 
 MUSCULOSKELETAL SYSTEM 
  Weakness 
  Bone pain 
  Bony deformities 
PROVISIONAL DIAGNOSIS 
INVESTIGATIONS 
  Hb 
  WBC – TC   DC   ESR 
  PCV  
  Platelet count 
  Urinalysis 
  Peripheral smear 
      S.Creatinine 
  Blood urea 
  S.electrolytes 
  S.Uric acid 
  Total protein   S.Albumin  ALP 
  S.Cholestrol 
  TSH 
  S.Fe    S.Ferritin  TIBC 
  ECG 
 
  CXR 
 
  USG Abdomen 
 
  Echocardiography 
 
  Renal biopsy 
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Name Age Sex Nature of 
renal disease 
Hb S.Creat P.Smear T.Protein
        
        
        
        
        
        
        
        
        
        
 
 
 
 
S.Albumin S.Cholest ALP S.Ca2+ S.Phos S.Uric acid S.Ferritin TIBC Stool  Occ. Bld 
         
         
         
         
         
         
         
         
         
         
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
1 Kantharubi 51 F Sec FSGS 7 4.5 MH 4.4 2.2 120 142 10.6 2.5 3.5 162 444 -
2 Rajamuthu 40 M ADPKD 6 12 NN 4.6 2.3 146 245 10.8 2.7 5.4 483 298 -
3 Varadhan 28 M CGN 6.4 7.4 NH 3.9 1.8 162 290 11.9 3 6 444 267 -
4 Chelladurai 31 M C/C TIN 8.4 4 NN 5.2 4.8 184 264 10.2 2.8 4.9 493 282 -
5 Gandhimathi 47 F DM Nephr 4.7 2.6 MH 4 1.9 250 282 9.2 2.9 6.4 103 370 -
6 Udayakumar 15 M IgA neph 7.5 3.2 NN 4.9 2.6 222 274 9 3.5 7.5 144 340 -
7 Valarmathi 46 F DM Nephr 5 3.9 MH 5.6 2.2 242 294 7.2 6.4 7.8 178 475 +ve
8 Rose 28 F CGN 8 5.6 NN 6 4 260 250 6.4 7 4.6 269 268 -
9 Premkumar 35 M CGN 6.6 5.2 MH 6.2 4.1 142 264 6.9 7.2 6 163 369 +ve
10 Hemalatha 30 F DM Nephr 8.6 7 NN 3.8 2.4 245 282 11.4 2.9 6.2 266 222 -
11 Rema 51 F CGN 7.4 6.6 NN 6.1 4.5 124 164 6.6 8 6.5 335 229 -
12 Purushotham 69 M Ischemic nephr 7 7 MH 5.9 4.2 178 224 6.3 7.1 4.8 132 562 +ve
13 Meena 55 F ADPKD 6 2.9 MH 4.4 4 185 284 7.2 2.8 8.2 165 569 -
14 Neelakandan 72 M DM Nephr 5.6 2.1 NN 3.8 2 270 296 7.8 6.9 4.9 289 442 -
15 Manikandan 67 M Ischemic nephr 7.3 6.8 NN 4.2 2.6 194 264 6.8 6.6 5.2 360 360 -
16 Priya 28 F C/C TIN 7 8.8 NN 4.8 2.8 225 268 7.9 3.3 7.2 335 383 -
17 Mallika 54 F DM Nephr 6 9.5 NH 4.1 2.6 292 184 6.5 7.9 4.2 169 320 -
18 Suresh 65 M Ischemic nephr 7.6 8.9 NN 5.5 2 184 289 7.8 3 4.3 285 351 -
19 Mohanbabu 52 M DM Nephr 7 11 NN 5.4 2.3 324 273 6.7 10 6.8 265 380 -
20 Sarammal 55 F CGN 7.3 12.3 NN 6.2 3.2 260 242 7.5 8.2 6.9 278 302 -
21 Mumtaz 22 F CGN 7.6 12.6 NN 6.4 3.2 198 216 7.9 6.8 6.2 468 325 -
22 Sasikumar 25 M IgA neph 7.8 1.9 MH 6.3 3.5 150 172 7.4 6.5 6.9 130 460 +ve
23 Parimala 55 F DM Nephr 6 10.3 NH 4 2.2 294 238 8 5.6 7.2 256 309 -
24 Ramu 26 M C/C TIN 8 4.2 DA 7.2 3.6 205 222 8.5 5.9 8.8 222 340 -
25 Narendran 65 M DM Nephr 7 5.3 NN 6.9 2.9 264 194 8.2 5.75 8.6 502 365 -
26 Mustaqkhan 56 M ADPKD 7.3 5.9 NN 7.2 4.2 192 205 6.5 5.28 9 562 348 -ve
27 Moorthy 55 M ADPKD 7.1 3.3 NN 6.6 3.8 180 164 7.3 6.6 9.5 493 369 -
28 Habela 34 F CGN 6 6.6 DA 4.5 3 165 256 7.2 7.4 10.5 160 382 -
29 Venkateshwaran 60 M DM Nephr 6.8 5.8 MH 7 3.2 295 284 11.8 5.1 8 122 396 +ve
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30 Ravi 60 M SOLITARY KIDNEY 7.9 4 NN 6.8 3.6 160 564 12 3.2 9.4 602 335 -
31 Govindaraj 60 M OBSTRUCTIVEUROPATHY 5.2 6.2 NN 4.6 2 149 256 8.6 7 7 545 336 -
32 Ghouse basha 48 M CGN 6.8 7.7 NH 4.4 2.2 220 324 9.2 2.9 7 402 295 +ve
33 Pushpa 56 F CGN 6.2 6.9 NN 4.8 2.1 240 131 6.8 15.1 6.9 666 278 -
34 Ajmilkhan 19 M ADPKD 6.6 7.3 NN 5.2 3.9 146 260 9.9 5.1 7.2 646 303 -
35 Palanivel 35 M C/C TIN 8.8 2.6 NN 5.5 3.6 172 420 9.4 5.2 7.8 660 256 -
36 Vijayan 20 M DM Nephr 6.5 10.2 MN 6 2.5 149 444 9.6 4.9 7.1 133 483 -
37 Muthusamy 45 M IgA neph 9.4 2.2 NN 4.9 2.9 182 424 11.2 4.2 6.2 180 373 -
38 Ramasamy 59 M DM Nephr 6.8 6.8 NH 5.2 3 165 165 7.6 7.9 3.5 393 325 -
39 Raja 56 M ADPKD 8.9 4.3 NN 2.5 1.8 122 90 8 6.5 3.7 405 330 -
40 Ramu 48 M ADPKD 6.2 2.9 NN 5.3 2.2 190 94 8.2 7.8 4 385 362 -
41 Ramadoss 77 M OBSTRUCTIVEUROPATHY 7 5.6 NH 3.3 1.9 162 89 6.8 7.8 4.9 162 313 -
42 Habela 18 F C/C TIN 8 2.8 MH 4.5 2.2 140 154 9 7.9 6.8 102 466 -
43 Alagappan 42 M DM Nephr 6.5 7.2 DA 6.5 3.5 220 168 8.9 5.5 6.6 122 330 -
44 Chinnasamy 49 M CGN 7 8.5 DA 7.2 4 185 222 7.2 5.8 7.4 106 304 -
45 Govindaraj 16 M IgA neph 6.9 9.2 NN 7 3.7 126 320 7.8 6.2 7.8 483 363 -
46 Kuppusamy 50 M DM Nephr 6 4 DA 4.4 2.9 225 149 6.4 6.9 8.2 128 498 -
47 Ezhumalai 40 M C/C TIN 10 4.2 NN 4.5 2.2 124 278 9.6 5.5 6.9 496 420 -
48 Punniyakotti 50 M DM Nephr 5.4 6 NH 6.2 3.2 165 562 11.2 5.2 7.1 138 390 -
49 Palani 34 M CGN 7 2.9 MH 7 3.6 184 440 10.2 5 7.6 166 660 -
50 Raja 48 M ADPKD 4.8 11 MH 7.1 3.8 192 429 11 3 7.2 182 487 -
NN            -   Normocytic Normochromic
NH            -   Normocytic Hypochromic
MH           -   Microcytic Hypochromic
S. Ca2      -   Serum Calcium
ALP          -   Alkaline Phosphatase
SP            -   Serum Phosphorus
TIBC        -   Total Iron Binding Capacity
CGN         -   Chronic Glomerulonephritis
C/C TIN   -   C/C Tubulointerstitial disease
ADPKD     -   Adult Polycystic Kidney Disease
